Seroprevalence of 34 human papillomavirus types in the German general population

PLoS Pathogens

Volumn 4, Issue 6, 2008, Pages

  Michael, Kristina M ^a   Waterboer, Tim ^a   Sehr, Peter ^a,d   Rother, Annette ^a,e   Reidel, Ulrich ^a,f   Boeing, Heiner ^b   Bravo, Ignacio G ^a,g   Schlehofer, Jörg ^a   Gärtner, Barbara C ^c   Pawlita, Michael ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f KLINIKUM AUGSBURG   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CAPSID PROTEIN; CAPSID PROTEIN L1;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ARTICLE; DNA VIRUS; EPITHELIUM; FEMALE; GERMANY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 1; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 41; HUMAN PAPILLOMAVIRUS TYPE 63; MAJOR CLINICAL STUDY; MALE; MUCOSA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; POPULATION; PRESCHOOL CHILD; PUBERTY; SCHOOL CHILD; SEROLOGY; SEROPREVALENCE; SEX RATIO; SKIN; VIRUS STRAIN; WART VIRUS; AGE; AGED; CHILD; EPIDEMIOLOGY; INFANT; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; SEX DIFFERENCE; VIRAL SKIN DISEASE; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE; PAPILLOMAVIRIDAE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; INFANT; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; SKIN DISEASES, VIRAL;

EID: 46449099188     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000091     Document Type: Article

References (115)

1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324: 17-27.
2. Forslund O (2007) Genetic diversity of cutaneous human papillomaviruses. J Gen Virol 88: 2662-2669.
3. zur Hausen H (1996) Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta 1288: F55-78.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
5. IARC (2007) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 90. Human Papillomaviruses (ISBN 978 92 832 1290 4), Lyon.
6. Jablonska S, Majewski S, Obalek S, Orth G (1997) Cutaneous warts. Clin Dermatol 15: 309-319.
7. Gassenmaier A, Fuchs P, Schell H, Pfister H (1986) Papillomavirus DNA in warts of immunosuppressed renal allograft recipients. Arch Dermatol Res 278: 219-223.
8. Jablonska S, Majewski S (1994) Epidermodysplasia verruciformis: immunological and clinical aspects. Curr Top Microbiol Immunol 186: 157-175.
9. Akgul B, Cooke JC, Storey A (2006) HPV-associated skin disease. J Pathol 208: 165-175.
10. Nindl I, Gottschling M, Stockfleth E (2007) Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 23: 247-259.
11. Grimmel M, de Villiers EM, Neumann C, Pawlita M, zur Hausen H (1988) Characterization of a new human papillomavirus (HPV 41) from disseminated warts and detection of its DNA in some skin carcinomas. Int J Cancer 41: 5-9.
12. Hirt L, Hirsch-Behnam A, de Villiers EM (1991) Nucleotide sequence of human papillomavirus (HPV) type 41: an unusual HPV type without a typical E2 binding site consensus sequence. Virus Res 18: 179-189.
13. Dillner J, Andersson-Ellstrom A, Hagmar B, Schiller J (1999) High risk genital papillomavirus infections are not spread vertically. Rev Med Virol 9: 23-29.
14. Cason J, Mant CA (2005) High-risk mucosal human papillomavirus infections during infancy & childhood. J Clin Virol 32 Suppl 1: S52-58.
15. Syrjanen S, Puranen M (2000) Human papillomavirus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med 11: 259-274.
16. Kashima HK, Mounts P, Shah K (1996) Recurrent respiratory papillomatosis. Obstet Gynecol Clin North Am 23: 699-706.
17. Dillner J (1999) The serological response to papillomaviruses. Semin Cancer Biol 9: 423-430.
18. Coursaget P (2003) Serology for human papillomavirus. Salud Publica Mex 45 Suppl 3: S361-366.
19. Iftner T, Villa LL (2003) Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr. pp 80-88.
20. Favre M, Majewski S, Noszczyk B, Maienfisch F, Pura A, et al. (2000) Antibodies to human papillomavirus type 5 are generated in epidermal repair processes. J Invest Dermatol 114: 403-407.
21. Favre M, Orth G, Majewski S, Baloul S, Pura A, et al. (1998) Psoriasis: A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 110: 311-317.
22. Majewski S, Jablonska S (2003) Possible involvement of epidermodysplasia verruciformis human papillomaviruses in the immunopathogenesis of psoriasis: a proposed hypothesis. Exp Dermatol 12: 721-728.
23. Steger G, Olszewsky M, Stockfleth E, Pfister H (1990) Prevalence of antibodies to human papillomavirus type 8 in human sera. J Virol 64: 4399-4406.
24. Stark S, Petridis AK, Ghim SJ, Jenson AB, Bouwes Bavinck JN, et al. (1998) Prevalence of antibodies against virus-like particles of Epidermodysplasia verruciformis-associated HPV8 in patients at risk of skin cancer. J Invest Dermatol 111: 696-701.
25. Bouwes Bavinck JN, Stark S, Petridis AK, Marugg ME, Ter Schegget J, et al. (2000) The presence of antibodies against virus-like particles of epidermodysplasia verruciformis-associated humanpapillomavirus type 8 in patients with actinic keratoses. Br J Dermatol 142: 103-109.
26. Weber F, Fuchs PG, Pfister HJ, Hintner H, Fritsch P, et al. (2001) Human papillomavirus infection in Netherton's syndrome. Br J Dermatol 144: 1044-1049.
27. Pfister H, Fuchs PG, Majewski S, Jablonska S, Pniewska I, et al. (2003) High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population. Arch Dermatol Res 295: 273-279.
28. Pfister H, zur Hausen H (1978) Seroepidemiological studies of human papilloma virus (HPV-1) infections. Int J Cancer 21: 161-165.
29. Pfister H, zur Hausen H (1978) Characterization of proteins of human papilloma viruses (HPV) and antibody response to HPV 1. Med Microbiol Immunol (Berl) 166: 13-19.
30. Kienzler JL, Lemoine MT, Orth G, Jibard N, Blanc D, et al. (1983) Humoral and cell-mediated immunity to human papillomavirus type 1 (HPV-1) in human warts. Br J Dermatol 108: 665-672.
31. Steele JC, Gallimore PH (1990) Humoral assays of human sera to disrupted and nondisrupted epitopes of human papillomavirus type 1. Virology 174: 388-398.
32. Viac J, Chomel JJ, Chardonnet Y, Aymard M (1990) Incidence of antibodies to human papillomavirus type 1 in patients with cutaneous and mucosal papillomas. J Med Virol 32: 18-21.
33. Carter JJ, Hagensee M, Taflin MC, Lee SK, Koutsky LA, et al. (1993) HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology 195: 456-462.
34. Carter JJ, Hagensee MB, Lee SK, McKnight B, Koutsky LA, et al. (1994) Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology 199: 284-291.
35. Anisimova E, Bartak P, Hamsikova E, Vonka V (1994) Comparative sensitivity of the immunoelectronmicroscopy test and ELISA with intact virions in detecting HPV-1 antibodies and age distribution of these antibodies among general population and in children's homes. Arch Virol 137: 157-160.
36. Cubie HA, Plumstead M, Zhang W, de Jesus O, Duncan LA, et al. (1998) Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old schoolgirls. J Med Virol 56: 210-216.
37. Hamsikova E, Ludvikova V, Smahel M, Sapp M, Vonka V (1998) Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int J Cancer 77: 689-694.
38. Feltkamp MC, Broer R, di Summa FM, Struijk L, van der Meijden E, et al. (2003) Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. Cancer Res 63: 2695-2700.
39. Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, et al. (2006) Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 98: 389-395.
40. Masini C, Fuchs PG, Gabrielli F, Stark S, Sera F, et al. (2003) Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals. Arch Dermatol 139: 890-894.
41. Struijk L, Hall L, van der Meijden E, Wanningen P, Bavinck JN, et al. (2006) Markers of cutaneous human papillomavirus infection in individuals with tumor-free skin, actinic keratoses, and squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 15: 529-535.
42. Termorshuizen F, Feltkamp MC, Struijk L, de Gruijl FR, Bavinck JN, et al. (2004) Sunlight exposure and (sero)prevalence of epidermodysplasia verruciformis-associated human papillomavirus. J Invest Dermatol 122: 1456-1462.
43. Wieland U, Ritzkowsky A, Stoltidis M, Weissenborn S, Stark S, et al. (2000) Communication: papillomavirus DNA in basal cell carcinomas of immuno-competent patients: an accidental association? J Invest Dermatol 115: 124-128.
44. Casabonne D, Michael KM, Waterboer T, Pawlita M, Forslund O, et al. (2007) A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121: 1862-1868.
45. Waterboer T, Abeni D, Sampogna F, Rother A, Masini C, et al. (2008) Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin. British Journal of Dermatology. In press.
46. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, et al. (2005) Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 51: 1845-1853.
47. Waterboer T, Sehr P, Pawlita M (2006) Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 309: 200-204.
48. Sehr P, Muller M, Hopfl R, Widschwendter A, Pawlita M (2002) HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 106: 61-70.
49. Sehr P, Zumbach K, Pawlita M (2001) A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 253: 153-162.
50. Rizk RZ, Christensen ND, Michael KM, Muller M, Sehr P, et al. (2008) Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 89: 117-129.
51. Williams HC, Pottier A, Strachan D (1993) The descriptive epidemiology of warts in British schoolchildren. Br J Dermatol 128: 504-511.
52. Larsson PA, Liden S (1980) Prevalence of skin diseases among adolescents 12-16 years of age. Acta Derm Venereol 60: 415-423.
53. Chen SL, Tsao YP, Lee JW, Sheu WC, Liu YT (1993) Characterization and analysis of human papillomaviruses of skin warts. Arch Dermatol Res 285: 460-465.
54. Hagiwara K, Uezato H, Arakaki H, Nonaka S, Nonaka K, et al. (2005) A genotype distribution of human papillomaviruses detected by polymerase chain reaction and direct sequencing analysis in a large sample of common warts in Japan. J Med Virol 77: 107-112.
55. Rubben A, Kalka K, Spelten B, Grussendorf-Conen EI (1997) Clinical features and age distribution of patients with HPV 2/27/57-induced common warts. Arch Dermatol Res 289: 337-340.
56. Egawa K (2005) Eccrine-centred distribution of human papillomavirus 63 infection in the epidermis of the plantar skin. Br J Dermatol 152: 993-996.
57. Iftner A, Klug SJ, Garbe C, Blum A, Stancu A, et al. (2003) The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 63: 7515-7519.
58. Egawa K, Honda Y, Inaba Y, Ono T (1998) Pigmented viral warts: a clinical and histopathological study including human papillomavirus typing. Br J Dermatol 138: 381-389.
59. Gissmann L, Pfister H, Zur Hausen H (1977) Human papilloma viruses (HPV): characterization of four different isolates. Virology 76: 569-580.
60. Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, et al. (2004) Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol 42: 3176-3184.
61. Speich N, Schmitt C, Bollmann R, Bollmann M (2004) Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from the west German area. J Med Microbiol 53: 125-128.
62. Partridge JM, Koutsky LA (2006) Genital human papillomavirus infection in men. Lancet Infect Dis 6: 21-31.
63. Dunne EF, Karem KL, Sternberg MR, Stone KM, Unger ER, et al. (2005) Seroprevalence of human papillomavirus type 16 in children. J Infect Dis 191: 1817-1819.
64. Marais D, Rose RC, Williamson AL (1997) Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa. J Med Virol 51: 126-131.
65. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, et al. (2003) Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 103: 413-421.
66. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, et al. (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186: 1396-1402.
67. Sukvirach S, Smith JS, Tunsakul S, Munoz N, Kesararat V, et al. (2003) Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 187: 1246-1256.
68. Sun Y, Eluf-Neto J, Bosch FX, Munoz N, Walboomers JM, et al. (1999) Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma. Cancer Epidemiol Biomarkers Prev 8: 935-940.
69. Wang SS, Schiffman M, Herrero R, Carreon J, Hildesheim A, et al. (2004) Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer 91: 1269-1274.
70. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, et al. (2003) Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 89: 1248-1254.
71. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML (2004) Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 31: 247-256.
72. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, et al. (2000) Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 87: 221-227.
73. Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, et al. (1993) Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 53: 919-923.
74. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, et al. (1996) Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 23: 333-341.
75. Schiffman MH (1992) Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 84: 394-398.
76. Klug SJ, Hukelmann M, Hollwitz B, Duzenli N, Schopp B, et al. (2007) Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol 79: 616-625.
77. Munoz N, Mendez F, Posso H, Molano M, van den Brule AJ, et al. (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190: 2077-2087.
78. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, et al. (1999) HPV testing in primary screening of older women. Br J Cancer 81: 554-558.
79. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, et al. (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92: 464-474.
80. Herrero R, Schiffman MH, Bratti C, Hildesheim A, Balmaceda I, et al. (1997) Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica 1: 362-375.
81. Lazcano-Ponce E, Herrero R, Munoz N, Cruz A, Shah KV, et al. (2001) Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 91: 412-420.
82. Eisemann C, Fisher SG, Gross G, Muller M, Gissmann L (1996) Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups. J Gen Virol 77 (Pt 8): 1799-1803.
83. Slavinsky J 3rd, Kissinger P, Burger L, Boley A, DiCarlo RP, et al. (2001) Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 12: 516-523.
84. Svare EI, Kjaer SK, Nonnenmacher B, Worm AM, Moi H, et al. (1997) Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 176: 876-883.
85. Thompson DL, Douglas JM Jr, Foster M, Hagensee ME, Diguiseppi C, et al. (2004) Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 190: 1563-1574.
86. van Doornum G, Prins M, Andersson-Ellstrom A, Dillner J (1998) Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex Transm Infect 74: 354-360.
87. Carter JJ, Wipf GC, Hagensee ME, McKnight B, Habel LA, et al. (1995) Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 172: 11-18.
88. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, et al. (1995) Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 33: 2058-2063.
89. Strickler HD, Kirk GD, Figueroa JP, Ward E, Braithwaite AR, et al. (1999) HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer 80: 339-344.
90. Bosch FX, de Sanjose S (2003) Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr. pp 3-13.
91. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, et al. (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991-998.
92. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, et al. (1996) The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174: 927-936.
93. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, et al. (1995) Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 172: 1425-1430.
94. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, et al. (2005) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14: 1157-1164.
95. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, et al. (2003) Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 77: 10186-10201.
96. Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, et al. (2003) Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 158: 486-494.
97. Schiffman M, Kjaer SK (2003) Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. pp 14-19.
98. Shamanin V, Glover M, Rausch C, Proby C, Leigh IM, et al. (1994) Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 54: 4610-4613.
99. de Villiers EM (1989) Heterogeneity of the human papillomavirus group. J Virol 63: 4898-4903.
100. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG (2000) The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol 74: 11636-11641.
101. de Koning MN, Struijk L, Bavinck JN, Kleter B, ter Schegget J, et al. (2007) Betapapillomaviruses frequently persist in the skin of healthy individuals. J Gen Virol 88: 1489-1495.
102. Kohler A, Forschner T, Meyer T, Ulrich C, Gottschling M, et al. (2007) Multifocal distribution of cutaneous human papillomavirus types in hairs from different skin areas. Br J Dermatol 156: 1078-1080.
103. Hazard K, Karlsson A, Andersson K, Ekberg H, Dillner J, et al. (2007) Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol 127: 116-119.
104. Antonsson A, Karanfilovska S, Lindqvist PG, Hansson BG (2003) General acquisition of human papillomavirus infections of skin occurs in early infancy. J Clin Microbiol 41: 2509-2514.
105. Boxman IL, Russell A, Mulder LH, Bavinck JN, ter Schegget J, et al. (2001) Association between epidermodysplasia verruciformis-associated human papillomavirus DNA in plucked eyebrow hair and solar keratoses. J Invest Dermatol 117: 1108-1112.
106. Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, et al. (2005) Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 125: 93-97.
107. Berkhout RJ, Bouwes Bavinck JN, ter Schegget J (2000) Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J Clin Microbiol 38: 2087-2096.
108. Clifford GM, Shin HR, Oh JK, Waterboer T, Ju YH, et al. (2007) Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 16: 1874-1879.
109. Gassenmaier A, Lammel M, Pfister H (1984) Molecular cloning and characterization of the DNAs of human papillomaviruses 19, 20, and 25 from a patient with epidermodysplasia verruciformis. J Virol 52: 1019-1023.
110. Pfister H, Gassenmaier A, Nurnberger F, Stuttgen G (1983) Human papilloma virus 5-DNA in a carcinoma of an epidermodysplasia verruciformis patient infected with various human papillomavirus types. Cancer Res 43: 1436-1441.
111. Yabe Y, Sakai A, Hitsumoto T, Kato H, Ogura H (1991) A subtype of human papillomavirus 5 (HPV-5b) and its subgenomic segment amplified in a carcinoma: nucleotide sequences and genomic organizations. Virology 183: 793-798.
112. Hepp KD (1995) Food consumption habits in Germany-the clinician's point of view. Metabolism 44: 14-17.
113. Heseker H, Hartmann S, Kubler W, Schneider R (1995) An epidemiologic study of food consumption habits in Germany. Metabolism 44: 10-13.
114. Mund K, Han C, Daum R, Helfrich S, Muller M, et al. (1997) Detection of human papillomavirus type 16 DNA and of antibodies to human papillomavirus type 16 proteins in children. Intervirology 40: 232-237.
115. Böhning D (1998) Allgemeine Epidemiologie. Oldenbourg Verlag: München, Wien.